Transcatheter Reduction or Surgery for Paravalvular Leak Repair?

Paravalvular leak is complication derived from incomplete sealing between the implanted prosthesis and the native annulus, which occurs in 5% of all patients who undergo mitral valve replacement and 10% of those who undergo transcatheter aortic valve replacement. This is the most frequent non-structural valve dysfunction.

¿Cateterismo o cirugía para el cierre del leak paravalvular?

While mild leaks can be asymptomatic, moderate to severe leaks are associated with heart failure, hemolytic anemia, and high rates of long-term mortality.

 

Surgical leak repair is indicated for these patients and it is associated with better outcomes than conservative treatment.


Read also: “Multivessel Disease and Severe Carotid Stenosis: How to Proceed”.


Transcatheter reduction has emerged as an alternative for patients for whom repeat surgery is extremely risky. In most single-center series and registries, transcatheter reduction was associated with a reduction in leak severity.

 

Given the recent advancements in transcatheter techniques (and the reduction of morbidity and mortality rates for repeat surgery), there is no evidence that may warrant choosing one technique over the other for the repair of severe paravalvular leak.

 

From 1994 to 2014, 231 patients underwent correction of severe paravalvular leak. Among them, 151 underwent repeat surgery and 80 underwent transcatheter reduction.


Read also: End of Discussion on the Impact of Pacemaker After TAVR?”


Propensity matching was used to compare both groups and assess the effect of either strategy on long-term rates of all-cause death and hospitalization for heart failure.

 

Over a 3.5-year follow-up, surgical correction was associated with an important reduction in all-cause death or hospitalization for heart failure compared with transcatheter reduction (hazard ratio [HR]: 0.28; 95% confidence interval [CI]: 0.18 to 0.44; p < 0.001). Upon consideration of mortality only, there was a trend favoring repeat surgery (HR: 0.61; 95% CI: 0.37 to 1.02; p = 0.06).

 

Conclusion

In patients with significant prosthetic leak, surgery was associated with better long-term outcomes compared with transcatheter reduction, but results in important peri-operative mortality and morbidity.

 

Editorial

The relative advantage of surgery over transcatheter reduction should be interpreted with caution, given the significant differences between groups. While the advantage was still present after adjustment, there may be inadvertent confounding variables, particularly among populations as different as those involved in this study.

 

Despite the relative advantage of surgery, its high peri-operative risk and the fact that benefits are only evident after 1 year warrant a careful assessment of life expectancy for each particular patient.

 

Original title: Surgery Versus Transcatheter Interventions for Significant Paravalvular Prosthetic Leaks.

Reference: Xavier Millán et al. J Am Coll Cardiol Intv 2017;10:1959-69.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...